INDEX

A
AMS 700 CX penile implant,
characteristics, 181, 182, 186
failure rate compared with Mentor
a-1, 192, 193, 195, 198
modeling procedure for
Peyronie’s disease,
caveats, 214, 216
complications, 212–214
development, 207, 208
technique, 208, 209, 211, 212
AMS 700 CXM, see Penile prosthesis
AMS 700 Ultrex, see Penile prosthesis
AMS 800, see Artificial urinary sphincter
AMS Ambicor, see Penile prosthesis
AMS Dynaflex, see Penile prosthesis
AMS Hydroflex, see Penile prosthesis
Artificial urinary sphincter (AUS),
AMS 800 features, 265, 266,
286–288
double-cuff sphincters, 165
female patients,
AMS 800 outcomes, 297–299
patient selecton and work-up,
288, 289
surgical techniques, 289–294,
296, 297
history of development, 164,
263–265, 286
male patients,
AMS 800 outcomes, 282, 283
history of patient, 267
indications, 266, 269, 270
Interstim neuromodulation program, 268
laboratory tests, 267–269
patient selection, 266–268

physical examination, 267
postoperative follow-up,
278, 279
problems and solutions,
erosion, 281, 282
infection, 281
pump squeezing, 279
sphincter activation, 279
urinary incontinence,
280, 281
urinary retention, 279, 280
radical prostatectomy
incontinence treatment,
98, 165, 269, 270
surgical techniques, 270–275,
277, 278
operation, 286–288
reliability, 164, 165
AUS, see Artificial urinary sphincter

B
Benign prostatic hyperplasia (BPH),
prevalence, 117
transurethral resection of prostate,
117, 118
urethral stent,
clinical trial comparing
transurethral resection
of prostate,
BPH impact index, 133,
134, 138
ejaculation, 126, 127
errection outcomes, 125, 126
errection pain, 125, 138
intercourse pain, 125
IPSS symptom scores, 132
long-term outcomes, 139
patient characteristics, 136
peak flow rate, 129, 138, 139
pressure flow studies, 132
procedure, 122, 123, 135
quality-of-life scores, 133
residual urine volume, 129, 131
safety, 123, 124, 137
study design, 121, 122
urethral pain, 124, 125, 137
endoscopic follow-up, 127
epithelialization, 127, 138
hyperplasia, 128
residual hypertrophic tissue, 128
stent migration, 128
insertion, 120, 121
Urovolume stent studies, overview, 118–120, 134, 135
Bioglass, injection therapy, 56, 63
Bladder replacement, grafts, historical perspective, 9
tissue engineering, beagle studies, 13, 14
cell regeneration, 10
compliance, 14
fetal tissue engineering, 22–24
immunocytochemical analysis, 14
matrices, 10, 11
strategies, 10
BPH, see Benign prostatic hyperplasia

C

Calcium hydroxylate, injection therapy, 57, 63
Chondrocyte, penile rod construction, 16, 17
Chondrogel, injection therapy, 59, 65, 68, 74
Collagen, urinary incontinence treatment with injection, characteristics, 72, 73
injection technique, 37–39
outcome data, 32, 33
radical prostatectomy patients, 96, 98
Contigen, injection therapy, 58, 65, 66, 67, 68, 70, 71
Corpus cavernosum, fibrosis, see also Peyronie’s disease, etiologies, 249
implantation surgery, complications, 259
corporotomy, 254, 255, 258
dilators, 251, 252
downsized prosthesis, 252–254
postoperative care, 259
reconstruction with synthetic grafts, 258
patient evaluation for prosthesis, history, 250
miscellaneous tests, 250
physical examination, 250
penile prosthesis indication, 161, 162, 176, 196
reoperation management in penile prosthesis implantation, 235, 237–239
sizing for penile prosthesis, 188
tissue engineering, cell regeneration, 10
immunocytochemical analysis, 15, 16
matrices, 10, 11
rationale, 15
strategies, 10
tissue harvesting, 16
Cymetra, injection therapy, 58

D

Dacomed Dura II, see Penile prosthesis
Deflux, injection therapy, 57, 65, 68
Detrusor-sphincter dyssynergia (DSD), complications, 101, 110
external sphincterectomy, 102, 111, 113
intravesicle pressure minimization, 101, 102
medical management, 102, 113
sphincter ablation, 102
treatment approach, 113
urethral stents,
  historical perspective, 102, 103
  permanent stents, 103–109
  removal, 112
  temporary stents, 109, 110, 113
Dextran, injection therapy, 57, 63
DSD, see Detrusor-sphincter dyssynergia
Dura II, development, 5
Durasphere, injection technique, 39
Durasphere, injection therapy, 56, 62, 64

E
ED, see Erectile dysfunction
Erectile dysfunction (ED),
  historical perspectives, 1, 6
  medical treatment, 219
  penile prosthesis, see Penile prosthesis
Peyronie's disease association, 202
Ethylene vinyl alcohol, injection therapy, 57, 68, 69
External sphincterectomy,
  detrusor-sphincter dyssynergia management, 102, 111, 113

F, G
Fat, injection therapy, 59, 65, 67, 68, 73
Flexiflate, development, 5
Gene therapy, tissue engineering, 24, 25

H, I
Hydroflex, development, 5
Hylagel-Uro, injection therapy, 58, 70

Incontinence, see Urinary incontinence
Injectable therapy, materials,
  bioglass, 56, 63
calcium hydroxylate, 57, 63
Chondrogel, 59, 65, 68, 74
collagen, 72, 73
Contigen, 58, 65, 66, 67, 68, 70, 71
Cymetra, 58
Deflux, 57, 65, 68
dextran, 57, 63
Durasphere, 56, 62, 64
ethylene vinyl alcohol, 57, 68, 69
fat, 59, 65, 67, 68, 73
Hylagel-Uro, 58, 70
Macroplastique, 56, 60–62, 64, 66, 68
outcomes by material,
  female incontinence, 64, 65
  male incontinence, 66, 67
  vesicoureteral reflux, 68
polyvinyl alcohol, 57, 68
silk-elastin polymer, 58, 70
small intestine submucosa, 58, 71, 72
smooth muscle, 59, 74
table, 56–59
Teflon, 55, 56, 60, 64, 66, 68
Urethrin, 56
Urocol, 56
Urologen, 58
UroVive, 57, 64, 66, 68, 69, 70
Teflon injection following radical prostatectomy, see Teflon injection therapy
tissue engineering,
  testicular functional replacement, 20, 22
urinary incontinence, 19, 20
vesicoureteral reflux, 19, 20
urinary incontinence treatment,
  antegrade injection, 33
carbon steel particles, 34
children, 33
collagen,
  injection technique, 37–39
  outcome data, 32, 33
DuraspHERE injection
  technique, 39
female versus male outcomes,
  74, 75
goals, 47, 48
historical perspectives, 29,
  30, 90, 91
patient selection,
  cystoscopy, 47
history, 45, 46
men, 35, 37
physical examination, 46
urodynamic testing, 46, 47
women, 34, 35
postoperative care, 51–53
silicone microimplants, 34
type III stress incontinence,
  30–32
urethral injection techniques,
  females, 48–50
  males, 50, 51
vesicoureteral reflux,
  patient evaluation, 53, 54
postoperative care, 54, 55
techniques, 54

K, L
Kidney, tissue engineering,
  approaches, 18, 19
  cell regeneration, 10
  challenges, 18
  matrices, 10, 11
  strategies, 10
Leydig cell, encapsulation
  and testicular functional
  replacement, 20, 22

M
Macroplastique, injection therapy,
  56, 60–62, 64, 66, 68
Mentor α-1,
  autoinflation, 195, 196
  corporeal fibrosis patients, 196
development and design, 192
failure rate compared with AMS
  700 CX, 192, 193, 195, 198
modeling procedure for
  Peyronie’s disease,
  caveats, 214, 216
  complications, 212–214
  development, 207, 208
  technique, 208, 209, 211, 212
  patient satisfaction, 196–198
Mentor Saline-Filled Testicular
  Prosthesis, see Testicular prosthesis

N–P
Neurogenic bladder, see
  Detrusor-sphincter dyssynergia
Omniphase, development, 5
Penile prosthesis,
  device classification and types,
  156–158
erosion,
  etiology, 251, 242
  management, 242, 243
  sites, 241, 242
  urethral erosion, 243
historical perspectives, 1–6,
  155, 156
indications,
  corpus cavernosum fibrosis,
    161, 162, 176, 249–255,
    258, 259
  erectile dysfunction, 189,
    198, 231, 232
  Peyronie’s disease, 159–161,
    176, 206–209,
    211–214, 216
  priapism, 162
  radical prostatectomy, 162, 163
  reconstruction, 159, 163, 170
  spinal cord injury, 163, 175, 176
infection,
  incidence, 220, 221
  pathogens, 222
  prevention,
    antibiotics, 222
Index

site preparation, 221, 222
urinary tract infection
treatment, 221
signs and symptoms, 223
treatment,
  antibiotics, 223, 225
removal of implant, 223,
  225, 226
salvage, 224–226, 228,
  239–241
inflatable prostheses,
  AMS 700 CX, 181, 182, 186,
    192, 193, 195
  AMS 700 CXM, 182, 186,
    187, 238, 252, 253
  AMS 700 Inflatable Penile
    Prosthesis, 180, 181
  AMS 700 Ultrex, 182–184, 239
  AMS Ambicor, 185
  AMS Dynaflex, 184, 185
  AMS Hydroflex, 184
history of development,
  179, 180
ideal implant
  characteristics, 186
implantation,
  autoinflation avoidance,
    188, 189
corporeal sizing, 188
infrapubic approach, 187
penoscratal approach, 188
indications for implantation,
  185, 186
one-piece prostheses, 184, 185
patient expectations, 187
reliability, 232
selection of device, 186
three-piece prosthesis,
  Mentor α-1, see Mentor α-1
  Mentor IPP, 191, 192
Peyronie’s disease
  management, see
    Peyronie’s disease
two-piece prosthesis, 185
mechanical devices,
  American Medical Systems
    products, 172, 177,
      180–185
  anesthesia for implantation, 175
  Dacomed Dura II, 173, 174
history of development,
  171, 172
  Mentor products, 172–173
  patient selection, 175, 176
  semirigid implant,
    advantages, 174, 175
    disadvantages, 176, 177
pain evaluation, 245
position problems, 243, 244
reliability, 167, 168
reoperation,
  fibrosis management, 235,
    237–239
  mechanical failure, 244, 245
  patient selection, 232, 233
  preparation of patients, 233
  repair rates, 219, 220
  salvage techniques following
    infection, 224–226,
      228, 239–241
surgery, 233, 234
tissue engineering,
  bending studies, 17, 18
  cell regeneration, 10
  chondrocytes for rod
    construction, 16, 17
  matrices, 10, 11, 17, 18
  strategies, 10
Peyronie’s disease,
  diagnosis, 203
  discovery, 201
  erectile dysfunction
    association, 202
  etiology, 201, 202
  medical treatment, 203, 204
  pathogenesis, 202
  patient evaluation, 203
penile prosthesis,
  Mentor α-1, 196

bulbourethral sling procedure, 98 chronic urinary catherization, 99 collagen injection, 96, 98 incidence of incontinence, 89 Teflon injection, outcomes, 96, 99 patient selection, 91, 92 technique, 92, 95 penile prosthesis, 162, 163

S
Silicone, implant safety, 142, 143, 153 Silimed oval carving block, see Testicular prosthesis Silk-elastin polymer, injection therapy, 58, 70 SIS, see Small intestine submucosa Small Carrion prosthesis, development, 4, 5 Small intestine submucosa (SIS), injection therapy, 58, 71, 72 Smooth muscle, injection therapy, 59, 74 Sphincter ablation, detrusor-sphincter dyssynergia management, 102 Spinal cord injury, causes, 101 neurogenic bladder, see Detrusor-sphincter dyssynergia penile prosthesis, 163, 175, 176

T
Teflon injection therapy, characteristics of particles, 56, 91 historical perspective, 90, 91 incontinence outcomes, females, 64 males, 66 indications, 55, 60 radical prostatectomy incontinence treatment, anatomy, 90 incidence of incontinence, 89 outcomes, 96, 97
patient selection, 91, 92
  technique, 92, 95
Urethrin, 56
vesicoureteral reflux, 68
Testicular prosthesis,
  contraindications, 146
  follow-up, 153
  historical perspectives, 141, 142
  ideal characteristics, 141
  indications, 145, 146
  Mentor Saline-Filled Testicular Prosthesis, 143, 145
morbidity,
  implant deflation or rupture, 151, 152
  infection, 151
  migration or migration, 152
  miscellaneous problems, 152, 153
  survey, 150
  silicone safety, 142, 143
Silimed oval carving block, 143
surgery,
  adults, 149, 150
  infants, 147, 149
  technique, 146, 147
Tissue engineering,
  bladder replacement,
    beagle studies, 13, 14
    cell regeneration, 10
    compliance, 14
    immunocytochemical analysis, 14
    matrices, 10, 11
    strategies, 10
corpora cavernosa, 15, 16
fetal tissue engineering, 22–24
genre therapy, 24, 25
injectable therapy,
  testicular functional replacement, 20, 22
  urinary incontinence, 19, 20
  vesicoureteral reflux, 19, 20
kidney, 18, 19
penile prosthesis, 16–18
ureter and urethra, 12

Transurethral resection of prostate (TURP),
  benign prostatic hyperplasia management, 117, 118
Urovolume stent comparative clinical trial for benign prostatic hyperplasia,
  BPH impact index, 133, 134, 138
ejaculation, 126, 127
erection outcomes, 125, 126
erection pain, 125, 138
intercourse pain, 125
IPSS symptom scores, 132
long-term outcomes, 139
patient characteristics, 136
peak flow rate, 129, 138, 139
pressure flow studies, 132
procedure, 122, 123, 135
quality-of-life scores, 133
residual urine volume, 129, 131
safety, 123, 124, 137
study design, 121, 122
urethral pain, 124, 125, 137
TURP, see Transurethral resection of prostate

U
Ureter, tissue engineering,
  cell expansion, 12
  cell regeneration, 10
  matrices, 10, 11
  matrix degradation, 12
  strategies, 10
Urethra, tissue engineering,
  cell expansion, 12
  cell regeneration, 10
  matrices, 10, 11
  matrix degradation, 12
  strategies, 10
Urethral stent,
  benign prostatic hyperplasia clinical trial comparing transurethral resection of prostate,
  BPH impact index, 133, 134, 138
ejaculation, 126, 127
ejaculation, 126, 127
erection outcomes, 125, 126
erecture outcomes, 125, 126
erection pain, 125, 138
intercourse pain, 125
IPSS symptom scores, 132
long-term outcomes, 139
patient characteristics, 136
peak flow rate, 129, 138, 139
pressure flow studies, 132
procedure, 122, 123, 135
quality-of-life scores, 133
residual urine volume, 129, 131
safety, 123, 124, 137
study design, 121, 122
urethral pain, 124, 125, 137
endoscopic follow-up, 127
encrustation, 127
epithelialization, 127, 138
hyperplasia, 128
residual hypertrophic tissue, 128
stent migration, 128
insertion, 120, 121
Urovolume stent studies, overview, 118–120, 134, 135
detrusor-sphincter dyssynergia management,
historical perspective, 102, 103
permanent stents, 103–109
removal, 112
temporary stents, 109, 110, 113
Urovolume stent development, 118, 119
Urethrin, injection therapy, 56
Urinary incontinence, see also
Artificial urinary sphincter, continence mechanisms, 44, 45
definition, 285
etiology, 300
injectable therapy,
antegrade injection, 33
carbon steel particles, 34
children, 33
collagen,
junction technique, 37–39
outcome data, 32, 33
Durasphere injection technique, 39
female versus male outcomes, 74, 75
goals, 47, 48
historical perspectives, 29, 30
materials, see Injectable therapy
outcomes by material, female, 64, 65
male, 66, 67
patient selection,
cystoscopy, 47
history, 45, 46
men, 35, 37
physical examination, 46
urodynamic testing, 46, 47
women, 34, 35
postoperative care, 51–53
silicone microimplants, 34
Teflon injection following radical prostatectomy, see Teflon injection therapy
tissue engineering, 19, 20
type III stress incontinence, 30–32
urethral injection techniques, females, 48–50
males, 50, 51
prevalence, 285
urethral dysfunction subtypes, 30–32
Urocol, injection therapy, 56
Urologen, injection therapy, 58
UroVive, injection therapy, 57, 64, 66, 68, 69, 70
Urovolume, see Urethral stent
V
Vesicoureteral reflux,
infectable therapy,
materials, see Injectable therapy
<table>
<thead>
<tr>
<th>outcomes by material, 68</th>
<th>ureterovesicle junction</th>
</tr>
</thead>
<tbody>
<tr>
<td>patient evaluation, 53, 54</td>
<td>physiology, 53</td>
</tr>
<tr>
<td>postoperative care, 54, 55</td>
<td>Vitamin E, Peyronie’s disease management, 203, 204</td>
</tr>
<tr>
<td>techniques, 54</td>
<td></td>
</tr>
<tr>
<td>tissue engineering, 19, 20</td>
<td></td>
</tr>
</tbody>
</table>